Organization Profile

You just read:

EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks

News provided by

Eli Lilly and Company

Jun 16, 2017, 05:10 ET